Over the past year, a clear pattern has emerged in my practice. Patients are no longer asking whether they should start a GLP-1 medication. They are arriving already on one. Often obtained online or from compounding pharmacies, sometimes without proper evaluation, dose titration, or a clear long-term plan. Not uncommonly, they present with avoidable symptoms such as severe nausea, vomiting, dehydration, or complications from rapid dose escalation.
In my practice, GLP-1 receptor agonists represent only a small, carefully selected component of a much broader longevity and performance medicine approach. I have always prioritized lifestyle optimization as the true foundation. This includes high-quality nutrition, resistance training, recovery strategies, stress management, and sleep. For the majority of my patients, who are already near optimal through dedicated lifestyle habits, these fundamentals alone deliver meaningful improvements in metabolic health, body composition, energy, and longevity.
I prescribe GLP-1 medications to a select group of patients. Typically those who have made strong lifestyle efforts yet still face significant metabolic roadblocks, or when the proven clinical benefits clearly justify their use. These medications are never positioned as a first-line or cosmetic solution. They serve as a powerful adjunct integrated into a comprehensive, individualized plan focused on preserving muscle, function, and long-term resilience.
I have managed it all firsthand. Patients who could not tolerate food. Those who needed IV fluids while traveling abroad. Individuals who lost significant muscle along with fat. And cases involving gallstones or perioperative complications that could have been prevented. At the same time, I have witnessed profound benefits: cardiovascular improvements, complete reversal of fatty liver disease on follow-up imaging, normalization of metabolic panels that had been abnormal for decades, dramatic reductions in alcohol consumption in patients who had struggled for years without that ever being the goal of treatment, meaningful mood elevation that patients describe as a mental clarity they had not experienced before, and life-changing transformations that extend far beyond the number on the scale.
The medications themselves are not the problem. The way they are frequently prescribed and used, without adequate oversight, monitoring, or supporting lifestyle structure, often is.
As a concierge internist and longevity physician with more than three decades of clinical experience on Manhattan’s Upper East Side, this is my updated perspective on one of the most consequential drug classes in modern medicine.
What GLP-1 Receptor Agonists Actually Do
GLP-1, or glucagon-like peptide-1, is a natural incretin hormone released by intestinal L-cells after eating. GLP-1 receptor agonists mimic this hormone. They bind to receptors throughout the body to suppress appetite, slow gastric emptying, enhance glucose-dependent insulin secretion, and suppress glucagon.
The result is substantial and sustained weight loss. This effect was first noted as a secondary finding in diabetes trials and is now a primary clinical application. But calling these medications weight loss drugs fundamentally undersells what they are. GLP-1 receptors are widely expressed in the heart, blood vessels, liver, kidneys, and brain. Their effects go well beyond caloric restriction, and what I see in my patients reflects that biology directly.
The most commonly encountered agents are semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, and tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity. Tirzepatide is a dual GLP-1 and GIP receptor agonist and has demonstrated superior weight loss in head-to-head comparisons with semaglutide.
The Indication Landscape Has Expanded Dramatically
This class has moved far beyond diabetes and obesity, and the clinical trial data are catching up to what physicians in active practice are already observing.
Cardiovascular disease. Semaglutide reduces major adverse cardiovascular events including myocardial infarction, stroke, and cardiovascular death in patients with overweight or obesity and established cardiovascular disease, even in the absence of diabetes. A meaningful portion of this benefit appears to be independent of weight loss, suggesting direct vascular and anti-inflammatory effects at the receptor level.
Chronic kidney disease. Semaglutide is now approved to reduce the risk of kidney failure and slow disease progression in patients with diabetes and chronic kidney disease.
Metabolic liver disease. GLP-1 receptor agonists produce significant reductions in hepatic fat and inflammation. Semaglutide has received accelerated approval for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. I have seen complete reversal of metabolic dysfunction-associated steatotic liver disease on follow-up imaging in my own patients.
Obstructive sleep apnea. Tirzepatide has received approval for obstructive sleep apnea in obese adults, reinforcing how broadly excess adiposity drives systemic disease and how broadly GLP-1 receptor activation can reverse it.
Neurologic and reward pathways. Emerging data and my own clinical observations show reduced alcohol consumption, decreased nicotine craving, and meaningful mood elevation with improved mental clarity. These effects appear linked to modulation of central reward circuits and are consistent with what I am seeing regularly in practice. They point toward a drug class whose central nervous system effects may ultimately prove as significant as its metabolic ones.
What strikes me consistently is that many of these benefits occur independently of how much weight a patient loses. They are not simply downstream of caloric restriction. They reflect direct GLP-1 receptor activation across the cardiovascular system, the liver, the kidneys, and the central nervous system. The weight loss is often the most visible outcome. It is not always the most important one.
What I Am Seeing in My Own Practice
The clinical reality is not theoretical for me. I have managed every complication described in this article, and I have witnessed outcomes that fully justify the enthusiasm surrounding this drug class. Both are real, and any honest perspective has to acknowledge both.
I have seen alcohol consumption decrease substantially in patients who had struggled with it for years, without that ever being the stated goal of treatment. I have seen metabolic dysfunction-associated steatotic liver disease reverse completely on follow-up imaging. I have watched blood pressure normalize, sleep apnea resolve, triglycerides drop dramatically, and patients who had been metabolically unwell for decades genuinely turn a corner. I have seen meaningful mood elevation that patients describe as a kind of mental clarity they had not experienced before.
I have also observed effects that are less discussed and deserve more attention. Some patients develop a modest but noticeable increase in resting heart rate. I regularly see decreases in heart rate variability on wearable monitoring, a finding consistent with sympathetic nervous system activation associated with this drug class. For patients who track heart rate variability as part of a recovery or performance protocol, this is a meaningful signal worth discussing before starting treatment and monitoring throughout. It is one more reminder that these medications are acting systemically across multiple organ systems, not locally, and that the full clinical picture requires ongoing attention.
The Risks I Manage Regularly
Gastrointestinal intolerance is the most frequent presenting complaint. It is typically dose-related and entirely preventable with appropriate titration. I routinely hear from patients who cannot maintain hydration or adequate nutrition, particularly while traveling, and who had no accessible clinical support when symptoms escalated. In fact, a meaningful number of my emergency house calls involve patients who started these medications on their own, escalated too quickly, and found themselves severely nauseated, vomiting, or dangerously dehydrated with nowhere to turn. That is not a rare edge case. It is a pattern I see regularly, and it is entirely avoidable with proper medical oversight from the start.
Lean mass loss is the most underappreciated risk in the longevity context. Significant weight reduction without a structured resistance training program and adequate protein intake leads to loss of muscle, not just fat. In older patients this translates into reduced strength, impaired function, and a worse long-term trajectory despite a lower number on the scale.
Facial volume loss, sometimes referred to colloquially as Ozempic face, is another consequence of rapid overall tissue loss that patients rarely anticipate. It is not a separate phenomenon but rather a visible manifestation of the same underlying problem. Weight lost too quickly and without adequate nutritional and training support tends to come from everywhere, including the face. Preserving lean mass through proper protein intake and resistance training mitigates this as well.
Gallstone formation accelerates with rapid weight loss through changes in bile composition and is frequently overlooked at the time of prescribing.
Bone density loss is a genuine concern, particularly in patients already at risk for osteopenia or osteoporosis, and underscores the importance of resistance training and nutritional support throughout treatment.
Perioperative risk has become increasingly relevant. Delayed gastric emptying requires modified anesthesia protocols, and failure to disclose GLP-1 use can create avoidable complications. Every patient I treat is instructed to inform their surgeon and anesthesiologist before any procedure.
The signal for medullary thyroid carcinoma observed in animal models has not been confirmed in humans, but these medications remain contraindicated in patients with a personal or family history of multiple endocrine neoplasia type 2 or medullary thyroid cancer.
Unsupervised use, particularly through online sources or compounding pharmacies, has amplified all of these risks. Many patients begin treatment without baseline labs, body composition assessment, or any structured plan for nutrition and training.
My Approach Before Prescribing
I do not treat these medications as cosmetic interventions.
A proper evaluation includes a comprehensive metabolic panel, lipid profile, hemoglobin A1c, thyroid function, renal function, liver enzymes, and a thorough gastrointestinal history. Given the cardiac autonomic effects I observe in practice, I also review baseline heart rate and heart rate variability data in patients who have them, and I discuss what changes to watch for once treatment begins.
Equally important is establishing a body composition baseline. In my office this is done using a professional-grade seca medical body composition analyzer, which provides a detailed assessment of fat mass, skeletal muscle mass, visceral adiposity, phase angle, and hydration status. This allows me to track not just how much weight is lost, but precisely what that weight consists of over time.
The distinction between fat loss and muscle loss is what ultimately determines whether a patient becomes genuinely healthier.
Exercise and Nutrition Are Non-Negotiable
This is where most protocols fail.
I do not prescribe these medications to patients unwilling to commit to resistance training and a protein-prioritized nutritional strategy. Without that foundation, patients lose weight, lose muscle, discontinue the medication, and regain weight with a worse body composition than where they started.
Protein intake is frequently underestimated. I typically target a minimum of 1.6 grams per kilogram of body weight per day, adjusted for age, training status, and metabolic context. Without this, the weight loss patients achieve can come at the expense of strength, metabolic health, and long-term resilience.
In select patients at higher risk for sarcopenia or accelerated muscle loss, I incorporate targeted supplementation strategies with evidence supporting preservation of lean mass. These include clinically selected, physician-dispensed formulations used to support muscle protein synthesis during periods of active weight loss. They are individualized and adjusted over time based on objective body composition data and functional performance, and are provided when appropriate as part of a structured treatment plan.
I routinely coordinate with performance-focused exercise specialists so that patients are supported physically, not only medically, throughout the process.
The medication is a tool. The outcome is determined by the structure built around it.
The Next Generation Is Already Here
The pipeline is evolving as rapidly as the clinical evidence base.
Retatrutide, a triple GLP-1, GIP, and glucagon agonist, has shown strong phase 3 results. In obesity trials that included patients with knee osteoarthritis, the highest dose delivered an average of 28.7 percent weight loss at 68 weeks along with major improvements in joint pain. In type 2 diabetes studies it achieved up to 16.8 percent weight loss at 40 weeks with no clear plateau observed.
Orforglipron, the first non-peptide oral GLP-1 receptor agonist, received approval in April 2026 for chronic weight management. Phase 3 data showed average weight loss of 12 to 15 percent, offering a convenient daily pill that can be taken without food or water restrictions and removing the injection barrier entirely.
MariTide is advancing through phase 3 with a long-acting profile that may allow for monthly or less frequent dosing, a meaningful adherence advantage for many patients.
CagriSema, which combines GLP-1 and amylin pathway signaling, achieved approximately 23 percent weight loss in phase 3 trials, though it did not outperform tirzepatide in recent head-to-head comparisons.
As this pipeline matures, the multi-organ reach of this drug class will only become more apparent. We are not looking at weight loss medications with incidental benefits. We are looking at systemic metabolic therapeutics whose full clinical profile is still being written.
The Bottom Line
GLP-1 receptor agonists represent a genuine inflection point in metabolic and longevity medicine. Their effects span the cardiovascular system, the liver, the kidneys, the brain, and the autonomic nervous system. I have seen this range firsthand: complete reversal of fatty liver disease, normalization of metabolic panels, dramatic reductions in alcohol consumption, mood elevation, and cardiac autonomic changes that remind us these molecules are doing far more than suppressing appetite. Many of these benefits occur independently of weight loss. That is what makes this drug class genuinely remarkable.
At the same time, access has expanded faster than oversight. A parallel prescribing ecosystem has emerged, often without the clinical infrastructure these medications require to be used responsibly. The patients who experience complications are not rare. They are showing up regularly, and in my practice some of them are showing up at my door for emergency house calls. The complications are almost always avoidable.
If you are considering this class of medication, the decision should begin with a comprehensive evaluation and a structured plan that includes body composition monitoring, ongoing clinical follow-up, and a clear strategy for preserving muscle mass and long-term function. When done correctly, the weight you lose can meaningfully improve your health and resilience. When done poorly, it can quietly undermine both.
Ready to Take the Next Step
If you are currently on a GLP-1 medication without a structured plan, not sure whether your current approach is optimal, or experiencing side effects without adequate support, I offer comprehensive metabolic evaluations that include body composition analysis and a personalized protocol designed to optimize your results while protecting muscle, function, and long-term health.
To schedule an appointment at my Upper East Side office, visit drprimas.com or call 212-737-1212.
